The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/96019

Please be advised that this information was generated on 2017-08-31 and may be subject to change.
Innate Immune Recognition of Mycobacterium tuberculosis

Johanneke Kleinnijenhuis, Marije Oosting, Leo A. B. Joosten, Mihai G. Netea, and Reinout Van Crevel

Department of Medicine, Radboud University Nijmegen Medical Centre, and Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands

Correspondence should be addressed to Reinout Van Crevel, r.vancrevel@aig.umcn.nl

Received 25 December 2010; Accepted 29 January 2011

Copyright © 2011 Johanneke Kleinnijenhuis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is a major health problem, with 10 million new cases diagnosed each year. Innate immunity plays an important role in the host defense against MTB, and the first step in this process is recognition of MTB by cells of the innate immune system. Several classes of pattern recognition receptors (PRRs) are involved in the recognition of MTB, including Toll-like receptors (TLRs), C-type lectin receptors (CLRs), and Nod-like receptors (NLRs).

Among the TLR family, TLR2, TLR4, and TLR9 and their adaptor molecule MyD88 play the most prominent roles in the initiation of the immune response against tuberculosis. In addition to TLRs, other PRRs such as NOD2, Dectin-1, Mannose receptor, and DC-SIGN are also involved in the recognition of MTB. Human epidemiological studies revealed that genetic variation in genes encoding for PRRs and downstream signaling products influence disease susceptibility, severity, and outcome. More insight into PRRs and the recognition of mycobacteria, combined with immunogenetic studies in TB patients, does not only lead to a better understanding of the pathogenesis of tuberculosis but also may contribute to the design of novel immunotherapeutic strategies.

1. Introduction

Tuberculosis (TB) is a major public health problem, with 10 million new cases diagnosed each year, causing a death toll of 2 million victims. However, from the estimated 2 billion persons individuals that have been initially infected with Mycobacterium tuberculosis, only 5% to 10% develop symptomatic TB.

The reason why some infected individuals develop active disease while others do not is not yet entirely understood. The role of inborn variability in susceptibility to tuberculosis has been accidentally proven by an episode that occurred almost a century ago, when in 1926 newborn infants from the town of Lübeck in Germany received live Mycobacterium tuberculosis (MTB) instead of the vaccine bacillus Calmette-Guérin (BCG). Some of the children became gravely ill, while others were unaffected [1]. This finding indicates that at least some individuals display an effective immune response to MTB and that this plays an important part in determining the outcome of the infection. In addition, this episode in young infants known to have immature adaptive immunity also suggests that the innate host defense is an important arm of antitubercular host defense.

Much has been learned during the last decade on the mechanisms through which the immune response to MTB is initiated. The first step is the recognition of mycobacteria as invading pathogens, followed by activation of innate host defense responses, and the subsequent initiation of adaptive immune responses. Knowledge about these processes is crucial for understanding the pathophysiology of tuberculosis, on the one hand, and for the development of novel strategies of vaccination and treatment such as immunotherapy on the other hand. This paper focuses on the first step of the immune response, which is the recognition of mycobacteria by cells of the innate immune system.

Initiation of the innate immune response starts with pattern recognition of microbial structures called pathogen-associated molecular patterns (PAMPs). Recognition of PAMPs is performed by germline-encoded receptors expressed mainly on immune cells termed pattern recognition receptors (PRRs) [2]. The first step in understanding the mechanisms of recognition of pathogenic bacteria is
1. The Mycobacterial Cell Wall. MTB is a slow-growing intracellular pathogen that can survive inside the macrophage of the host. MTB is an acid-fast bacterium due to the fact that the cell wall mainly consists of hydrophobic mycolic acids. This is a specific component of mycobacterial cell wall and makes up 50% of its dry weight. Due to this thick layer of mycolic acids, the entry of nutrients is impaire, which causes slow growth of mycobacteria, but it also increases cellular resistance to degradation through lysosomal enzymes [3]. The mycolic acids are distributed as a thick layer mostly at the external portions of the cell wall, while the internal layers of mycobacteria consist mostly of arabinogalactan, phosphatidyl-myco-inositol mannosides (PIMs), and peptidoglycans (Figure 1) [4]. Next to the mycolic acid layer, other components include mannose-containing biomolecules including mannose-capped lipoarabinomannan (Man-LAM), the related lipomannan (LM), and manno-glycoproteins [4]. Mannan and arabinomannan are present on the surface and form the outer capsule of this bacterium. Man-LAM, LM, and PIMs all share a conserved mannosyl-phosphatidyl-myco-inositol (MPI) domain that presumably anchors the structures into the plasma membrane [5].

Man-LAM, one of the most abundant mannans present on the cell surface, is an important virulence factor of MTB [6]. Man-LAM is a heterogeneous lipoglycan with a characteristic tripartite structure of a carbohydrate core, the MPI anchor, and various mannose-capping motifs. These mannose-capped motifs are characteristic for all pathogenic mycobacteria, and they are not present on fast-growing mycobacterial strains which are significantly less pathogenic. These strains have either uncapped LM or have phospho-myco-inositol caps (PILAM), which are known to display more robust immunostimulatory effects. PIMs can be divided into two groups dependent on the mannoe content, which determines its immunogenic effect [7, 8]. Also present on the cell surface are the manno-glycoproteins, which can also be secreted during growth.

1.2. Innate Immunity and Host Defense. After the inhalation of infected aerosols into the lungs of the host, the first encounter of mycobacteria is with alveolar resident macrophages. Mycobacteria that escape the initial intracellular destruction can multiply and disrupt the macrophage, after which chemokines are released, attracting monocytes and other inflammatory cells to the lung. Inflammatory monocytes will differentiate into macrophages, which readily ingest but do not destroy the mycobacteria [9]. In this stage of the infection, the mycobacteria grow logarithmically and blood-derived macrophages accumulate, but little tissue damage occurs. Two-to-three weeks after infection, T-cell immunity develops and antigen-specific T lymphocytes arrive, proliferate within the early lesions or tubercles, and release proinflammatory cytokines such as interferon-γ (IFNγ) that will activate macrophages to kill the intracellular mycobacteria. Subsequently, the early logarithmic bacillary growth stops, and central solid necrosis in these primary lesions or granuloma inhibits extracellular growth of mycobacteria. Several scenarios may follow, with infection becoming stationary or dormant in some individuals, or progressive in the lung, or with hematogenous dissemination in a minority of patients. In addition, reactivation can occur months or years afterwards, under conditions of failing immune surveillance [9]. Granuloma often contains central caseous necrotic tissue, which gives rise to cavities and aerogenic spread of mycobacteria.

The macrophage is a pivotal cell in these events, as it is involved in phagocytosis and killing of mycobacteria as well as in the initiation of adaptive T-cell immunity. Phagocytosis of MTB involves different receptors such as the scavenger receptors, the mannose receptor (MR), and complement receptors [10–13]. Phagocytosis can involve both uptake of the bacilli after opsonization with complement factors, or it can be initiated as a nonopsonic event. In vitro experiments have shown that complement receptor 3 (CR3) mediates approximately 80% of complement-opsonized MTB phagocytosis [12]. Nonopsonic phagocytosis is an important process in the primary infection of the lung, because complement factors are largely absent in the alveolar space [14].

Macrophages can eliminate mycobacteria through different mechanisms, such as production of reactive oxygen and nitrogen species, acidification of the phagosome, and phagosome fusion with the lysosomes [9]. The fate of intracellular mycobacteria is also influenced by autophagy, a cellular process though which cytoplasmic components, including organelles and intracellular pathogens, are sequestered in a double-membrane-bound autophagosome and delivered to the lysosome for degradation [15]. Activation of autophagy leads to phagosome maturation, an increased acidification in the phagosome, and killing of mycobacteria in macrophages.
[16]. However, once inside the cell, MTB often evades destruction by the innate microbial machinery [17], one of the main mechanisms being the inhibition of phagosome-lysosome fusion [18].

The interaction between MTB and cells of both the innate and adaptive immune system results in the secretion of chemokines and cytokines, the most important being tumor necrosis factor-α (TNFα), cytokines of the interleukin-1 family (IL-1β, IL-18), IL-12, and IFNγ. TNFα-deficient mice succumb rapidly after MTB infection, with significantly higher mycobacterial outgrowth in different organs compared to wild-type animals [19]. TNFα is also important for formation of granuloma, an important mechanism for containing and restricting the replication of the bacilli [19, 20]. The importance of IL-1β production is underlined by the fact that intact IL-1-mediated signals are essential components of the host defense to mycobacteria [21–23]. Infection of IL-1 receptor type 1 knockout mice with MTB is associated with lower production of IFNγ, defective granuloma formation, and lower survival [22].

IFNγ activates macrophages to kill and eliminate the mycobacteria. It also enhances their expression of MHC class II molecules, which results in improved antigen presentation to T cells. IFNγ is secreted by NK, CD4+, and CD8+ T cells upon release of endogenous IL-12 and IL-18 by macrophages and dendritic cells. The crucial importance of IFNγ for human antmycobacterial defence is demonstrated by the increased susceptibility to mycobacterial infections in patients with IFNγ receptor or IL-12 receptor deficiencies [24–26].

Various macrophages subsets have been identified with different potential functions. For example, alveolar macrophages, usually the first encounter with the mycobacterium, have an immune suppressive and poor antigen presenting ability [27, 28]. Two main subtypes are described, the classical and the nonclassical or alternative phenotypes. The classical route of differentiation induced by microbial products or IFNγ leads to induction of antimicrobial effects and production of proinflammatory cytokines as TNFα, IL-1β, IL12 (p40), and IL23 [29, 30]. This is in contrast to the nonclassical macrophages subsets, which lack antimicrobial activity and production of IL-12. These subsets have a poor antigen presenting capacity and can suppress cellular immunity by production of IL-10 [30]. The macrophages subset polarization may determine the outcome of the host response in skewing the pro- and anti-inflammatory immune response and subsequently in elimination of mycobacteria.

The first step in the activation of innate host defense begins with the pattern recognition of the pathogen. The PAMPs of MTB are sensed by specific PRRs, which in turn trigger production of proinflammatory cytokines and chemokines, phagocytosis and killing of the mycobacteria, and antigen presentation. This paper focuses on the role of the PRRs and downstream signaling for the recognition of MTB, including the intracellular mechanisms activated by PRRs. First, we will review specific evidence from in vitro studies and animal research. Then, we will discuss the human genetic studies done to assess the role of variation in PRR genes for the susceptibility to tuberculosis.

2. Recognition of Mycobacterium tuberculosis—Experimental Studies

The interaction between MTB and host cells is complex and, although extensively studied, not yet completely elucidated. Here we will focus on the PRRs that recognize specific PAMPs of mycobacteria and induce intracellular signals leading to cytokine production and initiation of adaptive immunity. A schematic representation is presented in Figure 2. Host receptors which are mainly involved in bacterial phagocytosis rather than immune recognition, such as complement receptors and scavenger receptors, go beyond the scope of this paper.

2.1. Toll-Like Receptors. Toll-like receptors (TLRs) are a family of PRRs consisting of 12 members in mammals. TLRs are expressed on the surface of the cell membrane or on the membrane of endocytic vesicles of mainly immune cells including macrophages and dendritic cells (DCs). Although the interaction of MTB with TLRs leads to phagocyte activation, the interaction itself does not lead to immediate ingestion of the mycobacteria. After the interaction of specific mycobacterial structures with TLRs, signaling pathways are triggered in which adaptor molecule myeloid differentiation primary response protein 88 (MyD88) plays an important role [31]. Subsequently, IL-1 receptor-associated kinases (IRAK), TNF receptor-associated factor (TRAF) 6, TGFβ-activated protein kinase 1 (TAK1), and mitogen-activated protein (MAP) kinase are recruited in a signaling cascade leading to activation and nuclear translocation of transcription factors such as the nuclear transcription factor (NF)-κB [32]. This leads to the transcription of genes involved in the activation of the innate host defense, mainly the production of proinflammatory cytokines as TNF, IL1β, and IL-12 and nitric oxide [33].

MyD88 plays a central role in the activation of the innate immune response to M. tuberculosis; compared to wild-type mice, MyD88 knockout mice are more susceptible to infection [21]. In addition to MyD88, TLR4 can induce intracellular signals through a second pathway, which is mediated by the adaptor molecule Toll/IL-1R (TIR) domain-containing adapter inducing interferon (IFN)-β (TRIF). Recently, this MyD88-independent, TRIF-dependent TLR4-signaling cascade was shown to be involved in the LPS-induced autophagy [34]. As the TLR4-induced activation of autophagy plays an important role in the phagosome-lysosome fusion, a process counteracted by MTB [34], it is tempting to speculate that the interaction between TRIF and autophagy is an important component of the innate host defense to mycobacteria.

The TLRs known to be involved in recognition of MTB are TLR2, TLR4, TLR9, and possibly TLR8 [35–40]. TLR2 forms heterodimers with either TLR1 or TLR6. These heterodimers have been implicated in recognition of mycobacterial cell wall glycolipids like LAM, LM, 38-kDa, and 19-kD mycobacterial glycoprotein, and phosphatidylinositol mannoside (PIM), triacylated (TLR2/TLR1), or diacylated (TLR2/TLR6) lipoproteins [39, 41, 42]. TLR2 is believed to be important in the initiation of innate host defense through
its stimulatory effects on TNFα production in macrophages [31, 38]. In turn, an important role for TLR2 and TLR6 but not TLR4 or TLR9, was found for the stimulation of IL-1β production [43]. TLR2 is also important for IL-12 release in macrophages, but not in DCs [44]. TLR2-/- mice show defective granuloma formation, and when infected with high doses of MTB, they have a greatly enhanced susceptibility to infection compared to the WT mice [45, 46]. In addition, TLR2-/- mice display defects in controlling chronic infection with MTB [46].

TLR4 is activated by heat shock protein 60/65 [37, 47], a protein that is secreted by a variety of MTB species. Studies with TLR4 transfected CHO cells and murine macrophages showed the importance of TLR4 in recognition of MTB [36, 39]. Macrophages of TLR4-deficient mice showed less, but not completely abolished, TNFα production. In vivo murine studies on the role of TLR4 in the recognition of MTB have shown conflicting results, even when the same mouse strain was used. Reiling et al. showed that TLR4-deficient mice, in contrast to TLR2 deficient mice, showed similar susceptibility to MTB infection compared to wild-type animals [45]. In contrast, Abel et al. reported higher mycobacterial outgrowth in lungs, spleen, and liver and a lower survival following infection compared to wild-type animals [48]. More studies are necessary to elucidate the source of these discrepancies and the role of TLR4 for MTB infection.
TLR9 recognizes unmethylated CpG motifs in bacterial DNA. In vitro studies showed that MTB-induced IL-12 release in dendritic cells was TLR9-dependent [38, 44]. In vivo experiments showed that when mice were infected with a high infectious dose of MTB, animals lacking TLR9 succumb earlier to infection than wild-type animals [38].

TLR8 is able to recognize single-stranded RNA from pathogens such as RNA viruses. Interestingly, Davila et al. demonstrated upregulation of TLR8 protein expression in macrophages after infection with BCG [40]. Until now, this is the only study addressing a potential role of TLR8, but the mechanism through which TLR8 recognizes MTB and signals intracellular remains unknown.

A partially redundant role of TLRs for the host defense against mycobacteria has been suggested, and it has been hypothesized that defects in multiple TLRs are necessary to unveil the role of these receptors for antimycobacterial defense. Indeed, TLR2 and TLR9 double knockout mice display greater defects of IL-12 and IFN-γ production in comparison with both single TLR knockout mice, and they succumb earlier to infection even when infected with a low inoculum of MTB [38].

2.2. NOD Like Receptors. The NOD like receptors (NLRs) family of proteins highly resembles the family of plant R (resistance) proteins, which have a crucial role in the defense against plant pathogens. The mammalian NLR family consists of more than twenty members with a conserved structure. The core of the molecule is formed by the nucleotide-binding domain, named NACHT (NAIP, CIITA, HET-E, and TP-1 [49]) or NOD (nucleotide oligomerization domain) domain. The C-terminal part consists of a series of leucin-rich repeats, which are thought to recognize the PAMPs of the pathogen and initiate activation of the molecule. The N-terminal portion of the molecule contains an effector domain of CARD (caspase activation and recruitment domain), PYRIN, or BIR (baculovirus inhibitor of apoptosis repeat domain) [50]. CARD-containing NLRs such as NOD1 and NOD2 are thought to form oligomers and then to recruit receptor-interacting protein 2 (RIP2) (or CARD containing kinase—RICK) through CARD-CARD interactions, which leads to the recruitment of NF-κB [51].

A major signalling pathway for the activation of the antimycobacterial host defense is represented by the inflammasome, that through activation of caspase-1 leads to processing of procytokines of the IL-1 family into the bioactive IL-1β and IL-18. Several PYRIN-domain containing NLRs (NALPs) can form different variants of the inflammasome containing either NLRP1, NLRP3 (cryopyrin), or NLRC4 (Ipaf) [52], as well as the adaptor protein ASC [53, 54]. A fourth type of inflammasome formed by the intracellular protein AIM2 is activated by intracytoplasmic DNA [55]. A recent study has shown that induction of IL-1β production by MTB is mediated by TLR2/TLR6 and NOD2 receptors, while caspase-1 is constitutively activated in human primary monocytes [43]. This is in contrast with the study of Master et al. that suggested that MTB inhibits inflammasome activation and IL-1β production [56]. However, these studies are not completely comparable as the latter study has used murine macrophage cell lines, in contrast to the human primary cells used by the former study. In addition, if MTB would inhibit IL-1β production even in normal hosts, this could not explain the increased susceptibility to infection of IL-1R-deficient mice [22].

NOD2 is an intracellular receptor-mediating stimulation of proinflammatory cytokine production by MTB. NOD2 is a receptor for bacterial peptidoglycans [57], and recently, we demonstrated its role in the recognition of mycobacteria [58, 59]. NOD2-deficient mice showed impaired production of proinflammatory cytokines and nitric oxide when infected with MTB. However, the susceptibility to MTB infection of NOD2-deficient mice is variable [60, 61].

2.3. C-Type Lectins. C-type lectins are a family of PRRs involved in the recognition of polysaccharide structures of pathogens. The mannose receptor (MR, CD206) consists of eight linked carbohydrate recognition domains and one cysteine-rich domain. MR is highly expressed on alveolar macrophages [62]. Mycobacterial stimulation through MR leads to production of the anti-inflammatory cytokines IL-4 and IL-13, inhibition of IL-12 production, and failure to activate oxidative responses [63, 64]. Man-LAM and other major components of the MTB cell wall like PIMs are natural mycobacterial ligands for MR. In addition, binding of MTB to MR induces phagocytosis, but phagosome-lysosome fusion is limited [65–67].

Differences at the level of mannosylation between MTB strains may also contribute to recognition by C-type lectins. Torrelles and Schlesinger showed that differences in virulence between MTB strains could be related to expression of Man-LAM on the cell wall [4]. Virulent MTB strains with less surface mannosylation do not use MR for phagocytosis but rely primarily for recognition and phagocytosis on CR3 after opsonisation. These strains are virulent because they display more other cell envelope components (like phenolic glycolipids and triacylglycerols) [68, 69]. These cell components regulate the cytokine response and demonstrate rapid intracellular growth and marked tissue damage [70, 71]. On the contrary, heavily mannosylated MTB strains such as the laboratory strain H37Rv use the MR receptor during invasion of the cell and are associated with a higher survival within the macrophage and an anti-inflammatory cytokine response. It is speculated that this type of recognition might lead to a latent stage of infection [4]. This might not be the case for all mycobacterial species; a mutant Mycobacterium bovis strain, which entirely lacked surface mannosase, showed a comparable cytokine profile as the nonmutant did [72].

2.4. DC-SIGN. Dendritic cell-specific intercellular adhesion molecule-3 grabbing nonintegrin (DC-SIGN, CD209) plays an important role in MTB-DC interaction. This receptor is mainly expressed on DCs and serves as both a PRR and an adhesion receptor, due to its functions in DC migration and DC-T-cell interactions [73, 74]. The carbohydrate recognition domain of DC-SIGN recognizes Man-LAM and lipomannans and the amount of Man-LAM determines the binding strength [64]. Recently, it was shown that α-glucan
(a dominant capsular polysaccharide) is also a ligand for DC-
SIGN [75]. After engagement of mycobacerial structures,
DC-SIGN promotes an anti-inflammatory immune response
by maturation of infected DCs and induction of IL-10
production [64]. Later, it was shown that DC-SIGN exerts its
immunosuppressive effects through induction of acetylation
of the NF-κB subunit p65 via Raf-1, but only in the presence
of simultaneous TLR stimulation [76].

2.5. Dectin-1. Dectin-1 is a receptor with an extracellular
carbohydrate recognition domain and an intracellular ITAM
domain. This receptor is mainly expressed on macrophages,
DCs, neutrophils, and a subset of T-cells. Dectin-1 mainly
recognizes β-glucans present in fungal pathogens, but it has
been suggested to play an important role in MTB recognition
as well. The precise PAMP that leads to the recognition
during dectin-1 is not known although some species of
MTB express α-glucan on the cell surface [77] as a ligand
for dectin-1. Murine bone marrow-derived macrophages
infected with either virulent or avirulent mycobacteria
produce TNF-α and IL-6 in a dectin-1-independent or
dectin-1-dependent manner, respectively [78]. A study with
DCs isolated from spleens showed that dectin-1 triggers
the production of IL-12 [79]. Several studies have shown
synergistic effects between TLR2 and dectin-1 for the recog-
nition of fungal pathogens [80, 81], but this remains to be
demonstrated in case of mycobacteria. Finally, a recent report
showed that dectin-1, independent of TLR2 recognition, is
important for the innate immunity recognition of MTB and
for inducing Th1 and Th17 responses [82].

3. Recognition of Mycobacterium tuberculosis—Human Genetic Studies

In order to have a complete picture of the role of PRRs for
the host defense to MTB, the results of in vitro and animal
studies need to be corroborated with studies in patients.
The association of host genetic factors with susceptibility or
resistance to TB has been studied extensively with candidate
gene approaches and genome-wide association studies.
These analyses have revealed several important candidate
genes for susceptibility to TB [83, 84]. For the scope of this
paper this section is limited to PRRs and their signaling
pathways only. Table 1 shows an overview of investigated
SNPs with or without association with TB.

The TLR2 gene is located on chromosome 4q32 and is
composed of two noncoding exons and one coding exon
[85]. More than 175 SNPs for the human TLR2 have
been reported. In a Turkish cohort, an association between
Arg753Gln and susceptibility to TB [86] was reported,
while this was not confirmed in two Asian cohorts due
to the absence of this particular polymorphism in those
populations [87, 88]. Arg753Gln seems to be present only in
Caucasian populations, with percentages ranging from 0 to
0.49% in East Asian populations [87, 89–91]. In a Tunisian
cohort, Arg677Trp showed an association with susceptibility
to TB [92], but these results were put in doubt by the
discovery of a pseudogene on which this SNP seems to be
located [93].

The TLR2 genotype 597CC has been correlated with
susceptibility to TB, especially with disseminated forms of
the infection (miliary and meningitis) caused by a particular
MTB genotype family (“the Beijing genotype”), in a cohort
of patients from Vietnam [107, 108]. A highly polymorphic
guanine-thymine repeat, located 100 base pairs upstream of
the TLR2 translation start site in intron 2, was correlated
with promoter activity and the expression of TLR2 on
CD14+ PBMCs (the shorter the repeat, the weaker the
promoter activity and the lower the expression of TLR2) for
both tuberculosis and nontuberculosis mycobacterial lung
infections in a Korean cohort [109, 110]. However, these
data could not be reproduced in a Taiwanese population
[111]. Another variation in genotype that seems to influence
TLR2 expression is –196 to –174 insertion/deletion, with a
recent study displaying an association with TB, while another
study showed a possible effect on development of systemic
symptoms [96, 111]. Many other polymorphisms in human
TLR2 are examined for their association with enhanced sus-
cceptibility to TB, but this requires further confirmation [96].

Since TLR1 and 6 form heterodimers with TLR2, SNPs in
these receptors might influence TLR2 signalling as well. One
example is Ile602Ser SNP in TLR1, which leads to aberrant
TLR1 cell trafficking, no functional TLR1 on the cell surface,
and which might influence the mycobacterial recognition
[112]. The 602I variant is overexpressed in African-
Americans infected with TB [94]. In addition, an association
between the TLR6 SNPs Ser249Pro and Thr361Thr and
MTB-induced cytokine production has been shown [100].

Immunogenetic studies have reported in two other TLR
genes: TLR4 and TLR8. In these genes, the genetic variation
associated with susceptibility to TB seems to be less pro-
nounced.

TLR4 Asp299Gly SNP showed an association with TB
in HIV positive Caucasians and Tanzanians, but not in a
Gambian population [97–99]. TLR8 has always been linked
with recognition of viral PAMPs, but in an immunogenetic
study in Indonesia, the TLR8 gene, which is located on the
X chromosome, was the only gene showing an association
with TB. This finding was confirmed in a second much larger
cohort from Russia and supported by functional data, as
discussed above [40]. Further studies are needed to confirm
these findings.

Besides the PRR receptor polymorphisms, SNPs in the
TLR signaling pathways may also influence susceptibility
to MTB. Khor et al. proposed that the Ser180Leu SNP in
the gene coding for TIR domain-containing adaptor protein
(TIRAP) was associated with a higher susceptibility to TB in
a cohort from West Africa [101] although the frequency of the
mutant allele was very rare. However, this association could
not be confirmed in a study involving 9000 individuals from
Ghana, Russia and Indonesia [102].

Regarding the other PRRs important for MTB recogni-
tion, the 871G and 336A variants located in the promoter
region of DC-SIGN were associated with protection against
tuberculosis in a South African cohort of patients [103].
This finding was, however, not confirmed in a Tunisian
cohort [105], while a later study even showed an associ-
ation in opposite direction (a protective effect of 336G)
Table 1: SNPs associated with susceptibility to tuberculosis.

<table>
<thead>
<tr>
<th>Receptor/signalling pathway</th>
<th>Gene</th>
<th>Amino acid</th>
<th>Association</th>
<th>No association</th>
</tr>
</thead>
<tbody>
<tr>
<td>TLR1</td>
<td>1805T&gt;G</td>
<td>Lle602Ser</td>
<td>[94]</td>
<td>[95]</td>
</tr>
<tr>
<td>TLR2</td>
<td>816T&gt;C</td>
<td>Asn199Asn</td>
<td>[86]</td>
<td>[95]</td>
</tr>
<tr>
<td></td>
<td>2258G&gt;A</td>
<td>Arg753Gln</td>
<td>[96]</td>
<td>[86, 87, 89, 91]</td>
</tr>
<tr>
<td>196 to 174 I/D*</td>
<td></td>
<td></td>
<td>[96]</td>
<td></td>
</tr>
<tr>
<td>TLR4</td>
<td>13843A&gt;G</td>
<td>Asp299Gly</td>
<td>[97, 98]</td>
<td>[95, 99]</td>
</tr>
<tr>
<td></td>
<td>1196C&gt;T</td>
<td>Thr399Ile</td>
<td>[95, 97]</td>
<td></td>
</tr>
<tr>
<td>TLR6</td>
<td>1083G&gt;C</td>
<td>Thr361Thr</td>
<td>[100]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>745C&gt;T</td>
<td>Ser249Pro</td>
<td>[100]</td>
<td></td>
</tr>
<tr>
<td>TLR8</td>
<td>4959C&gt;G</td>
<td>—</td>
<td>[40]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2921A&gt;G</td>
<td>—</td>
<td>[40]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3943A&gt;G</td>
<td>—</td>
<td>[40]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5088A&gt;G</td>
<td>Met1Val</td>
<td>[40]</td>
<td></td>
</tr>
<tr>
<td>TLR9</td>
<td>588A&gt;G</td>
<td>Lys196Lys</td>
<td>[96]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>411C&gt;T</td>
<td>His137His</td>
<td>[96]</td>
<td></td>
</tr>
<tr>
<td>TIRAP</td>
<td>539C&gt;T</td>
<td>Ser180Leu</td>
<td>[101]</td>
<td>[102]</td>
</tr>
<tr>
<td>DC-SIGN</td>
<td>336A&gt;G</td>
<td>—</td>
<td>[103, 104]</td>
<td>[105, 106]</td>
</tr>
<tr>
<td></td>
<td>601C&gt;T</td>
<td>—</td>
<td>[103, 105]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>871G&gt;C</td>
<td>—</td>
<td>[103]</td>
<td>[105]</td>
</tr>
<tr>
<td></td>
<td>939C&gt;T</td>
<td>—</td>
<td>[103, 105]</td>
<td></td>
</tr>
<tr>
<td>Neck region length</td>
<td></td>
<td>—</td>
<td>[103, 105, 106]</td>
<td></td>
</tr>
</tbody>
</table>

*I/D insertion/deletion.

Furthermore, genetic variation of the neck region of DC-SIGN (which supports the carbohydrate recognition domain) failed to show an association with tuberculosis susceptibility [105,113].

4. Conclusions and Future Research

Pattern recognition of MTB is a complex process in which a multitude of receptors recognize specific PAMPS of the microorganism. Recognition by specific receptors is followed by different intracellular signalling pathways, in order to integrate and induce an efficient activation of the innate host defense mechanisms. While activation through TLRs, NLRs and dectin-1 initiates essentially a proinflammatory response, signalling through the C-type lectins DC-SIGN or MR have mainly a modulatory function. The interplay between these pathways lead to finely tuned response of the immune system during the encounter with MTB.

One has to acknowledge that both in vitro and in vivo studies suffer from specific limitations, which may at least partly explain some discrepancies between experimental and immunogenetic studies in TB patients. In vitro studies use various cell types, murine macrophages (bone-marrow derived or alveolar), DCs or PBMCs. This can influence the outcome due to the preferential expression of specific receptors on different cell types. A second limitation is that in most in vitro studies only a single receptor is examined, isolated from its physiological environment, while the interplay between different pathways is probably one of the most relevant aspects of pathogen recognition. The role of the innate immune receptors involved in MTB recognition has often been studied in transfected cell lines, while animal models deficient of specific receptors show that these receptors can compensate for each other and sometimes display redundant roles [114–116].

In vivo animal studies have the disadvantage that the most commonly used murine models do not represent human TB; granuloma are not formed in these models, which is a crucial step in the latency of this disease. Rabbit and monkey models which are more similar with human TB are rarely used. Even human genetic studies have limitations in terms that these studies often lack the translation at the level of protein function, while in other situations, an important gene is highly conserved and lacks functionally relevant genetic variants that can be assessed.

While pattern recognition is an important component of the host response to infection with MTB, other factors are relevant as well, including the intrinsic capacity of macrophages to kill MTB, the distribution and function of different T-cell subsets, and regenerative and fibrotic tissue responses. These particular aspects were beyond the scope of this paper.

Humans and MTB have coevolved for millennia, and it is likely that a close relationship exist at the genomic level. Indeed, two studies have shown a direct association between the genetic characteristics of patients with tuberculosis and
their mycobacterial isolates [108, 117]. Polymorphisms in either TLR2 and SLC11A1 (NRAMP1) were associated with higher change of being infected with strains belonging to the evolutionary successful M. tuberculosis Beijing genotype. Globally, M. tuberculosis shows strong geographical differences [118, 119], and this might be triggered by evolutionary pressure from the innate immune system (“coevolution”). Besides M. tuberculosis, also, host immune gene polymorphisms show strong geographical differences. The studies of Caws et al. and Van Crevel et al. [108, 117] provide support for the hypothesis that evolutionary adaptation of particular M. tuberculosis lineages to certain human populations. For instance, in the case of TLR2 in the study of Caws et al., a certain M. tuberculosis genotype family might have a higher or lower affinity for TLR2 expressed in individuals with a particular TLR2 genotype, leading to differences in downstream signalling and subsequent events after recognition of M. tuberculosis. Clearly, this concept needs to be investigated in terms of innate immune recognition by examining a number of PRR genes in TB patients in relation to their infective M. tuberculosis genotypes. Comparing host-mycobacterial genotype relationships of more successful M. tuberculosis genotypes like the Beijing family and less successful genotypes will help increase the understanding of the concept of “coevolution”, virulence and innate host defense to M. tuberculosis.

Other important new areas of research related to innate immunity have been initiated recently, and their relationship with tuberculosis remains to be answered. One of the important cellular responses associated with antimycobacterial defense has been suggested to be the process of autophagy. Autophagy has been also shown to modulate the inflammation [120], especially through its interaction with the peptidoglycan receptor NOD2 [121, 122]. One important question to be answered is whether there is a role for autophagy in the induction of an inflammatory response by MTB. What is the explanation for the apparent redundancy in the pattern recognition, and which PRR is most important in which stage of the disease? Answers to these questions are needed in order to develop rational immunotherapeutic interventions like addition of TLR-agonists to candidate vaccines.

More can also be learned from studies in human patients. For instance, patients with advanced HIV-infection have virtually no T-cell immunity. However, even in settings which are hyperendemic for TB, some HIV-infected patients will never develop TB. Certainly, these individuals must have a very effective innate host response against MTB. A pivotal approach will be to combine genetic with functional studies; what does a SNP associated with susceptibility to TB mean in terms of the function of the immune response?

Another suggestion is to study an increased number of SNPs in more PRRs in the same population and to assess the cumulative effects of various combinations of SNPs to obtain a stronger association with disease. A striking observation is that only loss-of-function mutations are investigated. Could it be that gain-of-function mutations of PRRs might influence the immune response to MTB as well?

Finally, one of the most important challenges for the coming years is to translate the knowledge gained in the basic science of immune responses to mycobacteria into improved or novel immune-based treatment strategies, ranging from a better vaccine to immunotherapy.

Acknowledgments

Marije Oosting was supported within the framework of the Dutch Top Institute Pharma # D1-101. Mihai G. Netea was supported by a Vici Grant of the Netherlands Organization for Scientific Research (NWO). Reinout Van Crevel was supported by a Vidi grant of NWO.

References

Clinical and Developmental Immunology


